sacrosidase

(redirected from Sucraid)

sacrosidase

 [sak-ro´sĭ-dās]
an enzyme used as a substitute to replace the sucrase activity lacking in sucrase-isomaltase deficiency, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
References in periodicals archive ?
M2 PHARMA-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
Biopharmaceutical company QOL Medical LLC revealed on Tuesday the receipt of approval from the US Food and Drug Administration (FDA) to manufacture Sucraid (sacrosidase) Oral Solution for the treatment of congenital Sucrase-Isomaltase Deficiency at its wholly owned manufacturing facility in Clearwater, Florida.
Following this US FDA approval, the Sucraid drug shortage has been resolved as well as eliminating the need for informed consents, assents, physician acknowledgments and patient questionnaires for all Sucraid prescriptions.
In addition, the long-term supply of Sucraid continues to be the company's top priority.
According to the company, Sucraid (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).
Global Banking News-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
M2 EQUITYBITES-October 3, 2018-QOL Medical awarded US FDA approval to manufacture Sucraid (sacrosidase) Oral Solution at facility in Clearwater, Florida
The FDA has issued an expedited approval of a supplemental application that allows for changes in the manufacturing of Sucraid (sacrosidase) Oral Solution.
Sucraid provides drug replacement therapy for patients that have been diagnosed with a congenital (inherited) disease called Congenital Sucrase-Isomaltase Deficiency (CSID).
The agency is requesting the company implement measures designed to evaluate the risks of adverse events associated with the new supply of Sucraid.
"The FDA has expedited its approval of the newly manufactured Sucraid," said Julie Beitz, M.D., director, Office of Drug Evaluation Ill, the FDA's Center for Drug Evaluation and Research.
The increase results from pre tax gains associated with the previously announced divestments of Busulfex(R) (busulfan) Injection and Sucraid (R)(sacrosidase) oral solution.